<DOC>
	<DOCNO>NCT01967043</DOCNO>
	<brief_summary>This standard `` 3+3 '' Phase 1b study determine MTD Oraxol ( paclitaxel + HM30181 Methanesulfonate monohydrate ) subject advanced malignancy may metastatic unresectable measurable malignant lesion ( ) per RECIST Version 1.1 criterion .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Pharmacokinetics Activity Oraxol Subjects With Advanced Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>1 . Signed write informed consent 2 . ≥ 18 year age 3 . Histologically cytologically confirm solid tumor metastatic unresectable standard curative palliative measure exist longer effective . 4 . Measurable disease per RECIST Version 1.1 criterion . 5 . Adequate bone marrow reserve demonstrate Absolute neutrophil count ( ANC ) ≥1.5 x 10⁹/L Platelet count ≥ 100 x 10⁹/L Hemoglobin ( Hgb ) ≥ 9 g/L 6 . Adequate liver function demonstrate Total bilirubin ≤ 1.5 mg/dL ≤ 2.0 mg/dL subject liver metastasis Alanine aminotransferase ( ALT ) ≤ 3 x upper limit normal ( ULN ) ≤ 5x ULN liver metastasis present ALP ≤ 3 x ULN ≤ 5 x ULN bone metastasis present 7 . Adequate renal function demonstrate serum creatinine ≤ 1.5 x ULN , 24hr urine creatinine clearance calculation &gt; 60 mL/min 8 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 9 . Life expectancy least 3 month 10 . Subjects currently take prohibit medication 11 . Women must postmenopausal ( &gt; 12 month without menses ) surgically sterile ( ie , hysterectomy and/or bilateral oophorectomy ) must use effective contraception 1 . Have recover ≤ Grade 1 toxicity previous anticancer treatment previous investigational agent 2 . Received investigational agent within 14 day 5 halflives first study dose day , whichever longer . 3 . Women childbearing potential pregnant breast feeding . 4 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , myocardial infarction within last 6 month , unstable angina pectoris , cardiac arrhythmia , chronic pulmonary disease require oxygen , know bleeding disorder , psychiatric illness/social situation would limit compliance study requirement 5 . Significant uncontrolled cardiovascular disease bleed disorder 6 . Major surgery upper gastrointestinal ( GI ) tract , history GI disease medical condition , opinion investigator may interfere oral drug absorption 7 . Subjects know history allergy paclitaxel . Subjects whose allergy due IV solvent ( Cremophor® ) paclitaxel eligible study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>